Intrommune Therapeutics Completes Last Patient Last Visit in Phase 1 OMEGA Study

Intrommune Therapeutics, Inc., a clinical stage biotechnology company, has successfully completed the final visit of the last patient in the Phase 1 OMEGA Clinical Study for individuals with peanut allergy. This 48-week trial is specifically designed for adults with peanut allergies and aims to gather long-term safety data while determining the appropriate starting dose for INT301, an innovative..